Open Medicine,
Journal Year:
2023,
Volume and Issue:
18(1)
Published: Jan. 1, 2023
Abstract
The
objective
of
this
study
was
to
offer
new
approach
for
selection
persons
with
asymptomatic
bladder
cancer
(BC)
and
highly
risky
the
BC
occurrence.
Also,
it
is
a
part
screening
protocol
(study
ongoing).
Study
populations
were
100
newly
diagnosed
(diagnosis
maximum
1-year
old)
males
matched
(by
sex
age
±5
years)
controls
(not
oncology
patients
from
same
hospital).
A
hospital
based,
case–control
done.
Statistical
analysis
comprised
four
steps:
t
-test,
univariate
logistic
regression,
multivariate
scoring.
fifth
step
two
changes,
deleting
one
variable
addition
another
variable.
Six
variables
statistically
significant:
Caucasian
men
over
45
years
age,
tobacco
smoking
40
pack-years,
occupational
and/or
environmental
exposure
proved
carcinogens
20
years,
macrohematuria,
difficulty
urinating,
in
relatives
up
fourth
degree
kinships,
they
used
an
easy
fast
individuals
high
risk
occurrence
(optimal
at
population
level).
final
results
showed
significant
probability
(
p
<
0.001),
area
under
ROC
curve
0.913,
negative
predictive
values
89.7%
(95%
CI
10.3–100%),
specificity
78%.
Positive
value
80.5%
19.5–100%)
sensitivity
91%.
It
possible
recruit
(primary
prevention)
by
using
model,
as
well
(primordial
prevention).
This
first
second
ongoing
(urine
analysis).
International Journal of Molecular Sciences,
Journal Year:
2022,
Volume and Issue:
23(15), P. 8597 - 8597
Published: Aug. 2, 2022
The
non-muscle
invasive
bladder
cancer
tends
to
recur
and
progress.
Therefore,
it
requires
frequent
follow-ups,
generating
costs
making
one
of
the
most
expensive
neoplasms.
Considering
character
current
gold-standard
diagnostic
procedure,
white-light
cystoscopy,
efforts
find
an
alternative
method
are
ongoing.
Although
last
decade
has
seen
significant
advancements
in
urinary
biomarker
tests
(UBTs)
for
cancer,
international
guidelines
have
not
recommended
them.
Currently,
paramount
urgency
is
validate
test
with
best
specificity
sensitivity,
which
would
allow
optimizing
diagnosis,
prognosis,
a
treatment
plan.
This
review
aims
summarise
up-to-date
state
knowledge
relating
UBTs
new
developments
detection,
surveillance
their
potential
applications
clinical
practice.
Journal of Clinical Oncology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 14, 2025
Transurethral
resection
of
bladder
tumor
(TURBT)
is
the
initial
staging
procedure
for
new
cancers
(BCs).
For
muscle-invasive
(MIBCs),
TURBT
may
delay
definitive
treatment.
We
investigated
whether
treatment
can
be
expedited
MIBC
using
flexible
cystoscopic
biopsy
and
multiparametric
magnetic
resonance
imaging
(mpMRI)
staging.
conducted
a
prospective
open-label,
randomized
study
within
17
UK
hospitals
(registered
as
ISRCTN
35296862).
Participants
with
suspected
BC
were
randomly
assigned
1:1
to
TURBT-staged
or
mpMRI-staged
care,
minimization
factors
sex,
age,
clinician
visual
assessment
stage.
Blinding
was
not
possible.
Patients
unable/unwilling
undergo
mpMRI
previous
ineligible.
The
had
two
stages
separate
primary
outcomes
feasibility
time
correct
(TTCT)
MIBC,
respectively.
Between
May
31,
2018,
December
2021,
638
patients
screened,
143
participants
(n
=
72;
55
males,
15
MIBCs)
71;
53
14
MIBCs).
feasibility,
36
39
(92%
[95%
CI,
79
98])
underwent
mpMRI.
median
TTCT
significantly
shorter
12,
days
20
89]
v
n
14,
98
72
125]
TURBT,
log-rank
P
.02).
There
no
detriment
non-MIBC
(median
TTCT:
30,
8
25]
28,
10
29]
.67).
No
serious
adverse
events
reported.
mpMRI-directed
pathway
led
45-day
reduction
in
MIBC.
Incorporating
ahead
into
standard
beneficial
all
International Journal of Molecular Sciences,
Journal Year:
2022,
Volume and Issue:
23(16), P. 9148 - 9148
Published: Aug. 15, 2022
Early
detection
of
primary
bladder
cancer
(BCa)
is
vital,
because
stage
and
grade
have
been
generally
accepted
not
only
as
categorical
but
also
prognostic
factors
in
patients
with
BCa.
The
widely
screening
methods
for
BCa,
cystoscopy
urine
cytology,
unsatisfactory
diagnostic
accuracy,
high
rates
false
negatives,
especially
flat-type
BCa
low-risk
disease
cytology.
Currently,
liquid
biopsy
has
attracted
much
attention
being
compensatory
that
limited
power.
In
this
review,
we
survey
the
literature
on
focusing
circulating
tumor
cells
(CTCs),
urinary
cell-free
DNA
(ucfDNA),
microRNA
(umiRNA).
terms,
CTCs
umiRNA
are
determined
by
quantitative
analysis,
ucfDNA
relies
finding
genetic
epigenetic
changes.
ideal
biomarkers
should
be
highly
sensitive
detecting
produce
an
unfavorable
result;
however,
ucfDNA,
when
analyzed
using
a
panel
genes,
promising
results.
However,
given
small
cohort
size
most
studies,
no
conclusions
can
yet
drawn
about
biopsy's
immediate
application
to
clinical
practice.
Further
large
studies
validate
value
use
mandatory.
Aggregate,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 13, 2025
ABSTRACT
Urogenital
system
tumors
include
prostate
cancer,
bladder
ovarian
and
other
very
common
solid
tumor
diseases
with
high
morbidity
mortality.
The
unique
physiological
anatomical
features
of
the
urogenital
render
it
particularly
amenable
to
application
tissue
imaging
techniques
for
diagnostic
purposes.
advancement
aggregation‐induced
emission
(AIE)
materials
has
addressed
limitations
associated
conventional
fluorescent
that
are
prone
aggregation‐caused
quenching.
This
facilitated
development
innovative
AIE
characterized
by
enhanced
photostability,
an
increased
signal‐to‐noise
ratio,
improved
quality.
article
reviews
research
progress
biosensors
in
diagnosis
tumors.
It
mainly
involves
biomarker
vitro
fluorescence
such
as
uterine
which
based
on
biosensors.
In
addition,
a
comprehensive
description
biosensors’
synthesis
strategies
is
provided.
includes
detailed
elucidation
platforms
intracellular
mechanisms
basic
principles
AIE,
accompanied
presentation
quantitative
analysis
cell
results.
limitations,
challenges
suggestions
field
summarized,
prospect
prospected.
tumors,
also
provides
catalyst
exploring
characteristics
its
wide
disease
diagnosis.
European Urology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 1, 2025
Intravesical
therapy
is
central
to
managing
non-muscle-invasive
bladder
cancer
(NMIBC);
yet,
recurrence
and
progression
remain
common,
underscoring
the
need
for
new
treatments.
This
systematic
review
evaluates
clinical
trials
of
novel
intravesical
therapies
all
risk
categories
NMIBC.
A
comprehensive
literature
search
was
conducted
identify
assessing
effectiveness,
safety,
tolerability
The
focused
on
studies
published
from
2020
2024,
including
bacillus
Calmette-Guérin
(BCG)-unresponsive/refractory
disease
as
well
BCG-naïve
intermediate-risk
patients.
Mechanisms
action
drug
delivery
methods
were
summarized.
No
statistical
syntheses
performed
due
limited
comparative
data.
Out
2998
identified,
36
reported
efficacy
six
provided
patient-reported
outcomes
(PROs).
included
BCG-based
therapies,
chemotherapy
combinations,
chemical-drug
conjugates,
thermogels,
hyperthermic
chemotherapy,
osmotic
pumps,
gene
therapy.
Initial
response
rates
ranged
42%
85%
BCG-unresponsive/refractory
patients
65%
100%
treatment-naïve
12-mo
recurrence-free
survival
22%
83%
39%
92%,
respectively.
Progression
severe
toxicity
(grade
≥3)
rare
(0-17%
0-20%,
respectively).
PROs
stable.
limitations
early-phase
studies,
heterogeneous
outcome
assessments,
a
research
long-term
durability,
quality
life,
cost.
highlights
promising
However,
further
needed
refine
treatment
strategies
assess
outcomes,
economic
factors.
Future
should
include
multiarm,
multistage
designs
with
focus
patient-centered
outcomes.
